Glenmark Generics (Europe) Limited (GGEL), the European subsidiary of Glenmark Generics Limited, today announced the start of marketing of Ropinirole film-coated tablets and Lercanidipin in the UK.
`Ropinirole' is used for the symptomatic treatment of moderate to severe Idiopathic Restless Legs Syndrome while `Lercanidipin' is indicated for the treatment of mild to moderate essential hypertension, the company stated.
Glenmark Generics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Authority (MHRA) for Ropinirole film-coated tablets, Glenmark Pharmaceuticals said in a filing with the Bombay Stock Exchange (BSE).
Moderate to severe Idiopathic Restless Legs Syndrome is typically represented by patients who suffer insomnia or severe discomfort in the limbs.
GGEL has already commenced marketing and distribution of the product in the UK market in the 0.25 mg (12 tablets), 0.5 mg (28 tablets), 1 mg (84 tablets) and 2 mg (84 tablets), the release said.
Ropinirole is a non-ergoline D2/D3 dopamine agonist that stimulates striatal dopamine receptors.